Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00560755
Other study ID # V221-037
Secondary ID MRV01C2007-00243
Status Completed
Phase Phase 3
First received November 19, 2007
Last updated September 18, 2017
Start date October 24, 2007
Est. completion date November 24, 2008

Study information

Verified date September 2017
Source Merck Sharp & Dohme Corp.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary objective: To describe the safety profile of a second dose of ProQuad® manufactured with recombinant human albumin (rHA) when administered to children in their second year of life.

Secondary objectives: To describe the safety profile of a first dose of ProQuad® manufactured with rHA when administered to children in their second year of life.


Recruitment information / eligibility

Status Completed
Enrollment 3388
Est. completion date November 24, 2008
Est. primary completion date November 24, 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Months to 22 Months
Eligibility Inclusion Criteria:

- Healthy subject of either gender,

- Age from 12 to 22 months,

- Negative clinical history of infection with measles, mumps, rubella, varicella or zoster,

- Informed consent form signed by the parent(s) or by legal representative

- Parent(s) or legal representative able to attend all schedule visits with the subject and to understand and comply with the study procedures

Exclusion Criteria:

- Recent (= 3 days) history of febrile illness

- Prior receipt of measles, mumps, rubella and/or varicella vaccination, either alone or in any combination

- Recent (= 30 days) exposure to measles, mumps, rubella, varicella or zoster

- Prior known sensitivity/allergy to any component of the vaccine

- Severe chronic disease,

- Blood dyscrasias, leukaemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic system

- Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection

- Humoral or cellular immunodeficiency,

- Current immunosuppressive therapy

- Family history of congenital or hereditary immunodeficiency

- Hereditary problems of fructose intolerance

- Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition,

- Known active tuberculosis

- Recent (= 2 days) tuberculin test or scheduled tuberculin test through Visit 3

- Receipt of immunoglobulins or blood-derived products in the past 150 days

- Receipt of an inactivated vaccine in the past 14 days

- Receipt of a live vaccine in the past 28 days

- Any medical condition which, in the opinion of the investigator, might interfere with the evaluation of study objectives

- Participation in another clinical study in the past 30 days

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
ProQuad®
ProQuad® manufactured with recombinant human albumin (rHA) is an investigational combined attenuated live virus vaccine for vaccination against measles, mumps, rubella and varicella viruses.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme Corp.

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants Experiencing an Adverse Event (AE) After ProQuad® Dose 2 The percentage of participants experiencing an AE(s) for up to 28 days after the second ProQuad® injection was determined. Up to Day 70 (up to 28 days after ProQuad® Dose 2)
Primary Percentage of Participants Experiencing a Vaccine-related AE After ProQuad® Dose 2 The percentage of participants experiencing a vaccine-related AEs for up to 28 days after the second ProQuad® injection was determined. Up to Day 70 (up to 28 days after ProQuad® Dose 2)
Primary Percentage of Participants Experiencing a Solicited Injection-site AE After ProQuad® Dose 2 The solicited injection-site AEs erythema, swelling, and pain were monitored for 4 days after administration of ProQuad® Dose 2. Up to Day 46 (for 4 days following ProQuad® Dose 2)
Primary Percentage of Participants Experiencing a Unsolicited Injection-site AE After ProQuad® Dose 2 The percentage of participants experiencing a unsolicited injection-site AE(s) were monitored for up to 28 days after the second ProQuad® injection. Up to Day 70 (up to 28 days after ProQuad® Dose 2)
Primary Percentage of Participants Experiencing a Injection-site Rash of Interest AE After ProQuad® Dose 2 Injection-site rashes of interest, including measles-like, rubella-like, and vesicular, were monitored for up to 28 days after the second ProQuad® injection. Up to Day 70 (up to 28 days after ProQuad® Dose 2)
Primary Percentage of Participants Experiencing a Systemic AE After ProQuad® Dose 2 Systemic AEs were monitored for up to 28 days after the second ProQuad® injection. Up to Day 70 (up to 28 days after ProQuad® Dose 2)
Primary Percentage of Participants Experiencing a Vaccine-related Systemic AE After ProQuad® Dose 2 Vaccine-related systemic AEs were monitored for up to 28 days after the second ProQuad® injection. Up to Day 70 (up to 28 days after ProQuad® Dose 2)
Primary Percentage of Participants Experiencing a Non-injection-site Rash of Interest AE After ProQuad® Dose 2 Non-injection-site rashes of interest, including measles-like, rubella-like, varicella-like, and zoster-like rashes, were monitored for up to 28 days after the second ProQuad® injection. Up to Day 70 (up to 28 days after ProQuad® Dose 2)
Primary Percentage of Participants Experiencing a Mumps-like Illness After ProQuad® Dose 2 The percentage of participants experiencing a mumps-like illness for up to 28 days after the second ProQuad® injection was determined. Up to Day 70 (up to 28 days after ProQuad® Dose 2)
Primary Percentage of Participants Experiencing a Serious AE (SAE) After ProQuad® Dose 2 Serious AEs ere defined as any untoward consequence that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, is a congenital anomaly/birth defect, or is any other medically important event. Up to Day 84 (up to 42 days after ProQuad® Dose 2)
Primary Percentage of Participants Experiencing a Vaccine-related SAE After ProQuad® Dose 2 Vaccine-related SAEs were defined as any untoward consequence that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, is a congenital anomaly/birth defect, or is any other medically important event. Up to Day 84 (up to 42 days after ProQuad® Dose 2)
Secondary Percentage of Participants Experiencing a Solicited Injection-site AE After ProQuad® Dose 1 The solicited injection-site AEs erythema, swelling, and pain were monitored for 4 days after administration of ProQuad® Dose 1. From Day 1 to Day 4 (for 4 days following ProQuad® Dose 1)
Secondary Percentage of Participants Experiencing a Unsolicited Injection-site AE After ProQuad® Dose 1 Unsolicited injection-site AEs were monitored for up to 28 days after the first ProQuad® injection. Up to Day 28 (28 days after ProQuad® Dose 1)
Secondary Percentage of Participants With = 1 Rectal Temperature Reading = 38.0° C After ProQuad® Dose 1 The percentage of participants with at least 1 rectal temperature reading = 38.0° C was determined. Up to Day 28 (28 days after ProQuad® Dose 1)
Secondary Percentage of Participants Experiencing a Systemic AE After ProQuad® Dose 1 Systemic AEs were monitored for up to 28 days after the first ProQuad® injection. Up to Day 28 (28 days after ProQuad® Dose 1)
See also
  Status Clinical Trial Phase
Completed NCT04183114 - Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study) Phase 2/Phase 3
Completed NCT00092430 - Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Phase 3
Completed NCT02196285 - Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella Phase 1
Completed NCT00313950 - Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Phase 4
Completed NCT00384397 - A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Phase 3
Completed NCT00402831 - ProQuad® Intramuscular vs Subcutaneous Phase 3
Completed NCT01878435 - Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya N/A
Completed NCT01777529 - Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Phase 4
Terminated NCT00258726 - Immune Responses to Two Dose Varivax +/- MMR-II Phase 1/Phase 2
Completed NCT00109278 - A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED) Phase 2
Not yet recruiting NCT05771779 - Co-administration Study of OCV, TCV and MR Phase 3
Completed NCT02880865 - Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine Phase 4
Completed NCT01681992 - Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Phase 3
Completed NCT00751348 - Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Phase 3
Completed NCT01702428 - Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Phase 3
Completed NCT00969436 - Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Phase 3
Completed NCT00566527 - Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Phase 3
Completed NCT00127010 - Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Phase 3
Completed NCT00388440 - Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Phase 4
Completed NCT03148990 - Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella Phase 2/Phase 3